Konjenital diyafragma hernisi tedavisinde doku mühendisliği

Öz

Doğumsal diyafragmatik herni (CDH), en sık karşılaşılan konjenital anomalilerden biri olup abdominal organların göğsüne herniyasyonuna neden olan diyafram kusurunun varlığı olarak tanımlanmaktadır. Son yıllarda ileri tedavi stratejileri getirilmesine rağmen hayatta kalma oran, % 70 civarında kalmışve geliştirilememiştir. KKH'de kötü sonuçların başlıca belirleyicileri pulmoner hipoplazi ve pulmoner hipertansiyondur. Akciğer fonksiyonlarını ve sağkalımı geliştirmek için çeşitli cerrahi müdahaleler ve yeni tıbbi tedaviler denmektedir, ancak istenilen seviyeden daha az orandadır. Protez materyali ile diyafragma defektinin onarımının, takip sırasında yüksek komplikasyonlar ve rekürrens oranları ile ilişkili olduğu tespit edilmiştir. Bu nedenle, rejeneratif ilaç hem hipoplazi akciğerlerde hücresel fonksiyonu indükleyerek (kök hücre tedavisi) hem de işlevsel bir miyojenik yama (doku mühendisliği) geliştirerek, CDH'de alternatif bir tedavi stratejisi olarak düşünülmektedir.Solunum yetmezliğine sebep olan ciddi pulmoner hipoplazi ve hipertansiyon ile doğan CDH'li yenidoğanların yaklaşık % 30'unun hayatta kalması pulmoner hipoplazi derecesi ile ilişkili olduğundan, bu dereceyi prenatal olarak değerlendirmek büyük önem taşır. Prenatal ultrasonografi (US) ve manyetik rezonans görüntüleme (MRI) iki ana tanı aracıdır. CDH'de pulmoner hipoplazi ve hipertansiyonu iyileştirmek için çeşitli doğum öncesi tedavi stratejileri denendi. Vitamin A, kortikosteroidler, C vitamini, E, N-asetilsistein, fosfodiesteraz inhibitörleri, glukagon benzeri peptit 1 agonistleri ve tirozin kinaz inhibitörleri gibi antioksidanlar hayvan çalışmalarında analiz edildi ve değişken sonuçlar gösterdi. İnsanlar üzerinde çok az çalışma olduğu için, bu terapilerin klinik yararlarını teyit edebilmek için ileri aşama araştırmalar insanlar üzerinde olmalıdır. Doğumdan sonra bebeğe destekleyici tedavisinin yanı sıra solunum yetmezliği durumunda tercihen yüksek frekanslı salınımlı ventilasyon ile solunum desteği de uygulanmalıdır. Eksojen kök hücreler, özellikle AFS hücreleri akciğer gelişimini hem çeşitli pulmoner hücre tiplerine entegre ederek, hem de anti-inflamatuvar ve immünomodülatör etkiler yoluyla parakrin modele göre veya doğal progenitör hücreleri aktive ederek geliştirebilir. Ancak, akciğer hasarının altında yatan mekanizmayı ve kök hücrelerin moleküler tepkisini anlamak için, özellikle de insanlarda yapılacak daha ileri araştırmalara ihtiyaç vardır. Doğum öncesi tarama yöntemlerindeki ilerlemeler sayesinde, artık gebelikteki en büyük genetik bozuklukların çoğunu tespit etme ve postnatal dönemde optimal tedavi stratejisi sunma olanaği bulunmaktadır. CDH'li çocukların tedavisinde rejeneratif tıbbın uygulanmasına ilişkin hayvan çalışmalarının sonuçları gelecek vadetmektedir. Yakın gelecekte özellikle güvenlik ve etik konular çerçevesinde yoğunlaşan daha ileri çalışmaların  desteğiyle, klinik olarak uygulanması için gerekli kanıtlar bu çalışmalar ile sağlanacaktır.

Anahtar Kelimeler

• doğumsal,diyafragma hernisi,doku mühendisliği

Tissue engineering in the treatment of congenital diaphragmatic hernia

Öz

Congenital diaphragmatic hernia (CDH) is one of the most common major congenital anomalies and is described as the presence of a diaphragmatic defect that leads the herniation of abdominal organs into the chest. Although advanced treatment strategies are introduced over the recent years, they have not really improved the survival rate which stayed at around 70%. Major determinants of poor outcome in CHD are pulmonary hypoplasia and pulmonary hypertension. Various surgical interventions and novel medical therapies are attempted to improve lung function and survival but remains less than desired. Repair of the diaphragmatic defect with prosthetic materials was found to be associated with high rates of complications and recurrences during follow-up. Therefore, regenerative medicine should be considered as an alternative treatment strategy in CDH both by inducing cellular function in the hypoplastic lungs (stem cell therapy) and by developing a functional myogenic patch (tissue engineering). Nearly 30% of infants who have CDH born with severe pulmonary hypoplasia and hypertension which may lead to respiratory failure and prompt mechanical support, since the survival of these newborns relate to the degree of pulmonary hypoplasia, accurate prenatal evaluation of this degree is of paramount importance. The two main diagnostic tools which could be used for this purpose are prenatal ultrasound (US) and magnetic resonance imaging (MRI). Various prenatal treatment strategies have been tried to cure pulmonary hypoplasia and hypertension in CDH. Vitamin A, corticosteroids, antioxidants such as vitamin C, E, N-acetylcystein, phosphodiesterase inhibitors, glucagon-like peptide 1 agonists and tyrosine kinase inhibitors have all been analyzed in animal studies and demonstrated variable results. Since there are very few human studies, further researches should be performed in humans confirming the clinical benefit of these therapies. Due to the advancements in prenatal screening methods, we, now have the ability to detect most of the major genetic disorders in gestation and have chance to provide optimal treatment strategy in the postnatal period. Results of the animal studies regarding the application of regenerative medicine for treatment of children with CDH are encouraging. Hopefully, with the support of further studies focusing especially on safety and ethical issues, the near future will provide us the evidence necessary for their application in our clinical practice.  

Anahtar Kelimeler

• congenital,diaphragmatic hernia,tissue engineering

Kaynakça

1. 1. De Coppi P. Regenerative medicine for congenital malformations. J Pediatr Surg 2013;48(2):273-280.
2. 2. Atala A. Regenerative medicine strategies. J Pediatr Surg 2012;47(1):17-28.
3. 3. Tovar JA. Congenital diaphragmatic hernia. Orphanet J Rare Dis 2012;7:1.
4. 4. Rocha GM, Bianchi RF, Severo M et al. Congenital diaphragmatic hernia. The post-neonatal period. Part ii. Eur J Pediatr Surg 2008;18(5):307-312.
5. 5. Jeanty C, Kunisaki SM, MacKenzie TC. Novel non-surgical prenatal approaches to treating congenital diaphragmatic hernia. Semin Fetal Neonatal Med 2014;19(6):349-356.
6. 6. Nobuhara KK, Lund DP, Mitchell J, Kharasch V, Wilson JM. Long-term outlook for survivors of congenital diaphragmatic hernia. Clin Perinatol 1996;23(4):873-887.
7. 7. Waag KL, Loff S, Zahn K et al. Congenital diaphragmatic hernia: A modern day approach. Seminars in pediatric surgery 2008;17(4):244-254.
8. 8. Fauza DO. Tissue engineering in congenital diaphragmatic hernia. Seminars in pediatric sur-gery 2014;23(3):135-140.

9. 9. Jesudason EC, Connell MG, Fernig DG, Lloyd DA, Losty PD. Early lung malformations in congenital diaphragmatic hernia. J Pediatr Surg 2000;35(1):124-127; discussion 128.
10. 10. Fuchs JR, Kaviani A, Oh JT et al. Diaphragmatic reconstruction with autologous tendon engi-neered from mesenchymal amniocytes. J Pediatr Surg 2004;39(6):834-838; discussion 834-838.
11. 11. Montedonico S, Sugimoto K, Felle P, Bannigan J, Puri P. Prenatal treatment with retinoic acid promotes pulmonary alveologenesis in the nitrofen model of congenital diaphragmatic hernia. J Pedi-atr Surg 2008;43(3):500-507.
12. 12. Conconi MT, Bellini S, Teoli D et al. In vitro and in vivo evaluation of acellular diaphragmatic matrices seeded with muscle precursors cells and coated with vegf silica gels to repair muscle defect of the diaphragm. J Biomed Mater Res A 2009;89(2):304-316.
13. 13. Prendergast M, Rafferty GF, Milner AD et al. Lung function at follow-up of infants with surgi-cally correctable anomalies. Pediatr Pulmonol 2012;47(10):973-978.
14. 14. Kitano Y, Okuyama H, Saito M et al. Re-evaluation of stomach position as a simple prognostic factor in fetal left congenital diaphragmatic hernia: A multicenter survey in japan. Ultrasound Obstet Gynecol 2011;37(3):277-282.
15. 15. Ruano R, Takashi E, da Silva MM, Campos JA, Tannuri U, Zugaib M. Prediction and probabil-ity of neonatal outcome in isolated congenital diaphragmatic hernia using multiple ultrasound parame-ters. Ultrasound Obstet Gynecol 2012;39(1):42-49.
16. 16. Barnewolt CE, Kunisaki SM, Fauza DO, Nemes LP, Estroff JA, Jennings RW. Percent predict-ed lung volumes as measured on fetal magnetic resonance imaging: A useful biometric parameter for risk stratification in congenital diaphragmatic hernia. J Pediatr Surg 2007;42(1):193-197.
17. 17. Walleyo A, Debus A, Kehl S et al. Periodic mri lung volume assessment in fetuses with con-genital diaphragmatic hernia: Prediction of survival, need for ecmo, and development of chronic lung disease. AJR Am J Roentgenol 2013;201(2):419-426.
18. 18. Bebbington M, Victoria T, Danzer E et al. Comparison of ultrasound and magnetic resonance imaging parameters in predicting survival in isolated left-sided congenital diaphragmatic hernia. Ultra-sound Obstet Gynecol 2014;43(6):670-674.
19. 19. Thebaud B, Barlier-Mur AM, Chailley-Heu B et al. Restoring effects of vitamin a on surfactant synthesis in nitrofen-induced congenital diaphragmatic hernia in rats. Am J Respir Crit Care Med 2001;164(6):1083-1089.
20. 20. Okoye BO, Losty PD, Fisher MJ, Wilmott I, Lloyd DA. Effect of dexamethasone on endothe-lial nitric oxide synthase in experimental congenital diaphragmatic hernia. Arch Dis Child Fetal Neona-tal Ed 1998;78(3):F204-208.
21. 21. Taira Y, Miyazaki E, Ohshiro K, Yamataka T, Puri P. Administration of antenatal glucocorti-coids prevents pulmonary artery structural changes in nitrofen-induced congenital diaphragmatic her-nia in rats. J Pediatr Surg 1998;33(7):1052-1056.
22. 22. Gonzalez-Reyes S, Martinez L, Martinez-Calonge W, Fernandez-Dumont V, Tovar JA. Effects of antioxidant vitamins on molecular regulators involved in lung hypoplasia induced by nitrofen. J Pediatr Surg 2006;41(8):1446-1452.
23. 23. Shue EH, Schecter SC, Gong W et al. Antenatal maternally-administered phosphodiesterase type 5 inhibitors normalize enos expression in the fetal lamb model of congenital diaphragmatic her-nia. J Pediatr Surg 2014;49(1):39-45; discussion 45.
24. 24. Romani-Perez M, Outeirino-Iglesias V, Gil-Lozano M, Gonzalez-Matias LC, Mallo F, Vigo E. Pulmonary glp-1 receptor increases at birth and exogenous glp-1 receptor agonists augmented surfac-tant-protein levels in litters from normal and nitrofen-treated pregnant rats. Endocrinology 2013;154(3):1144-1155.
25. 25. Ghofrani HA, Morrell NW, Hoeper MM et al. Imatinib in pulmonary arterial hypertension pa-tients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182(9):1171-1177.
26. 26. Lally KP, Bagolan P, Hosie S et al. Corticosteroids for fetuses with congenital diaphragmatic hernia: Can we show benefit? J Pediatr Surg 2006;41(4):668-674; discussion 668-674.
27. 27. Frenckner B, Broome M, Lindstrom M, Radell P. Platelet-derived growth factor inhibition--a new treatment of pulmonary hypertension in congenital diaphragmatic hernia? J Pediatr Surg 2008;43(10):1928-1931.
28. 28. Fujino Y, Takezawa J, Nishimura M, Imanaka H, Taenaka N, Yoshiya I. High-frequency oscil-lation for persistent fetal circulation after repair of congenital diaphragmatic hernia. Crit Care Med 1989;17(4):376-377.
29. 29. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respirato-ry failure in newborn infants. Cochrane Database Syst Rev 2008(3):CD001340.
30. 30. Clark RH, Hardin WD, Jr., Hirschl RB et al. Current surgical management of congenital dia-phragmatic hernia: A report from the congenital diaphragmatic hernia study group. J Pediatr Surg 1998;33(7):1004-1009.
31. 31. Nguyen TL, Le AD. Thoracoscopic repair for congenital diaphragmatic hernia: Lessons from 45 cases. J Pediatr Surg 2006;41(10):1713-1715.
32. 32. Meehan JJ, Sandler A. Robotic repair of a bochdalek congenital diaphragmatic hernia in a small neonate: Robotic advantages and limitations. J Pediatr Surg 2007;42(10):1757-1760.
33. 33. Fung ME, Thebaud B. Stem cell-based therapy for neonatal lung disease: It is in the juice. Pe-diatr Res 2014;75(1-1):2-7.
34. 34. Angelini A, Castellani C, Ravara B et al. Stem-cell therapy in an experimental model of pul-monary hypertension and right heart failure: Role of paracrine and neurohormonal milieu in the re-modeling process. J Heart Lung Transplant 2011;30(11):1281-1293.
35. 35. Anversa P, Kajstura J, Leri A, Loscalzo J. Tissue-specific adult stem cells in the human lung. Nat Med 2011;17(9):1038-1039.
36. 36. Garcia O, Carraro G, Navarro S et al. Cell-based therapies for lung disease. British medical bulletin 2012;101:147-161.
37. 37. Kajstura J, Rota M, Hall SR et al. Evidence for human lung stem cells. The New England jour-nal of medicine 2011;364(19):1795-1806.
38. 38. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98(5):1076-1084.
39. 39. Pozzobon M, Ghionzoli M, De Coppi P. Es, ips, msc, and afs cells. Stem cells exploitation for pediatric surgery: Current research and perspective. Pediatr Surg Int 2010;26(1):3-10.
40. 40. van Haaften T, Byrne R, Bonnet S et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med 2009;180(11):1131-1142.
41. 41. Roubelakis MG, Pappa KI, Bitsika V et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: Comparison to bone marrow mesenchymal stem cells. Stem Cells Dev 2007;16(6):931-952.
42. 42. Iritani I. Experimental study on embryogenesis of congenital diaphragmatic hernia. Anat Em-bryol (Berl) 1984;169(2):133-139.
43. 43. Greer JJ, Cote D, Allan DW et al. Structure of the primordial diaphragm and defects associated with nitrofen-induced cdh. J Appl Physiol (1985) 2000;89(6):2123-2129.
44. 44. Pederiva F, Ghionzoli M, Pierro A, De Coppi P, Tovar JA. Amniotic fluid stem cells rescue both in vitro and in vivo growth, innervation, and motility in nitrofen-exposed hypoplastic rat lungs through paracrine effects. Cell Transplant 2013;22(9):1683-1694.
45. 45. Di Bernardo J, Maiden MM, Hershenson MB, Kunisaki SM. Amniotic fluid derived mesen-chymal stromal cells augment fetal lung growth in a nitrofen explant model. J Pediatr Surg 2014;49(6):859-864; discussion 864-855.
46. 46. Kamata S, Usui N, Kamiyama M et al. Long-term follow-up of patients with high-risk congeni-tal diaphragmatic hernia. J Pediatr Surg 2005;40(12):1833-1838.
47. 47. Congenital Diaphragmatic Hernia Study G, Lally KP, Lally PA et al. Defect size determines survival in infants with congenital diaphragmatic hernia. Pediatrics 2007;120(3):e651-657.
48. 48. Bianchi A, Doig CM, Cohen SJ. The reverse latissimus dorsi flap for congenital diaphragmatic hernia repair. J Pediatr Surg 1983;18(5):560-563.
49. 49. Lally KP, Paranka MS, Roden J et al. Congenital diaphragmatic hernia. Stabilization and repair on ecmo. Annals of surgery 1992;216(5):569-573.
50. 50. Moss RL, Chen CM, Harrison MR. Prosthetic patch durability in congenital diaphragmatic her-nia: A long-term follow-up study. J Pediatr Surg 2001;36(1):152-154.
51. 51. Laituri CA, Garey CL, Valusek PA et al. Outcome of congenital diaphragmatic hernia repair depending on patch type. Eur J Pediatr Surg 2010;20(6):363-365.
52. 52. Orlando G, Wood KJ, Stratta RJ, Yoo JJ, Atala A, Soker S. Regenerative medicine and organ transplantation: Past, present, and future. Transplantation 2011;91(12):1310-1317.
53. 53. Fauza DO, Marler JJ, Koka R, Forse RA, Mayer JE, Vacanti JP. Fetal tissue engineering: Dia-phragmatic replacement. J Pediatr Surg 2001;36(1):146-151.
54. 54. Kunisaki SM, Fuchs JR, Kaviani A et al. Diaphragmatic repair through fetal tissue engineering: A comparison between mesenchymal amniocyte- and myoblast-based constructs. J Pediatr Surg 2006;41(1):34-39; discussion 34-39.
55. 55. Kunisaki SM, Freedman DA, Fauza DO. Fetal tracheal reconstruction with cartilaginous grafts engineered from mesenchymal amniocytes. J Pediatr Surg 2006;41(4):675-682; discussion 675-682.
56. 56. Kunisaki SM, Fuchs JR, Steigman SA, Fauza DO. A comparative analysis of cartilage engi-neered from different perinatal mesenchymal progenitor cells. Tissue Eng 2007;13(11):2633-2644.
57. 57. De Coppi P, Bartsch G, Jr., Siddiqui MM et al. Isolation of amniotic stem cell lines with poten-tial for therapy. Nat Biotechnol 2007;25(1):100-106.
58. 58. Deprest J, De Coppi P. Antenatal management of isolated congenital diaphragmatic hernia to-day and tomorrow: Ongoing collaborative research and development. Journal of pediatric surgery lec-ture. J Pediatr Surg 2012;47(2):282-290.
59. 59. Piccoli M, Franzin C, Bertin E et al. Amniotic fluid stem cells restore the muscle cell niche in a hsa-cre, smn(f7/f7) mouse model. Stem cells (Dayton, Ohio) 2012;30(8):1675-1684.
60. 60. Turner CG, Klein JD, Steigman SA et al. Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. J Pediatr Surg 2011;46(1):57-61
61. 61. Kunisaki SM, Armant M, Kao GS, Stevenson K, Kim H, Fauza DO. Tissue engineering from human mesenchymal amniocytes: A prelude to clinical trials. J Pediatr Surg 2007;42(6):974-979; discussion 979-980.
62. 62. Steigman SA, Armant M, Bayer-Zwirello L et al. Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. J Pediatr Surg 2008;43(6):1164-1169